GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (FRA:UQ1) » Definitions » Gross-Profit-to-Asset %

uniQure NV (FRA:UQ1) Gross-Profit-to-Asset % : -1.00% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. uniQure NV's annualized Gross Profit for the quarter that ended in Dec. 2023 was €-7.87 Mil. uniQure NV's average Total Assets over the quarter that ended in Dec. 2023 was €789.65 Mil. Therefore, uniQure NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was -1.00%.


uniQure NV Gross-Profit-to-Asset % Historical Data

The historical data trend for uniQure NV's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV Gross-Profit-to-Asset % Chart

uniQure NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.03 9.02 88.69 14.09 0.28

uniQure NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.28 1.72 0.54 0.18 -1.00

Competitive Comparison of uniQure NV's Gross-Profit-to-Asset %

For the Biotechnology subindustry, uniQure NV's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


uniQure NV's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where uniQure NV's Gross-Profit-to-Asset % falls into.



uniQure NV Gross-Profit-to-Asset % Calculation

uniQure NV's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=2.031/( (665.486+762.659)/ 2 )
=2.031/714.0725
=0.28 %

uniQure NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-7.872/( (816.642+762.659)/ 2 )
=-7.872/789.6505
=-1.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


uniQure NV Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of uniQure NV's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


uniQure NV (FRA:UQ1) Business Description

Industry
Traded in Other Exchanges
Address
Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

uniQure NV (FRA:UQ1) Headlines

No Headlines